Pressure BioSciences Announces Approval to Manufacture Hemp-Derived CBD Products in Massachusetts, Including Their Revolutionary CBD Nanoemulsions

Canopy CBD Farms, a MA-licensed US processor/manufacturer/distributor of hemp-derived CBD products, received state approval covering the manufacture of PBI’s CBD nanoemulsions for sale to MA and domestic formulators and manufacturers of CBD products derived from hemp

SOUTH EASTON, MA / ACCESSWIRE / August 11, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of pressure-based specialty testing instruments, consumables, and services broadly for the biopharmaceutical, nutraceutical, cosmetic, agrochemical, and pharmaceutical industries. ‘food and beverage, today announced the approval of its South Easton MA facility to manufacture custom, compatible, hemp-derived CBD nanoemulsions under the processing/manufacturing license of its business partner, Canopy CBD Farms, Fitchburg , MA.

Canopy CBD Farms (“CCF”) is a Massachusetts licensed hemp processing and manufacturing company. Anticipating the future of government regulations, CCF has strategically aligned with FDA-registered laboratories and manufacturers to provide the highest standards and quality of hemp-derived CBD products. Canopy CBD Farms serves pharmaceutical and medical research companies that wish to establish white label/local manufacturing partnerships with cGMP and GLP manufacturers. CCF’s partnerships will increase wholesale and retail distribution channels, with a ready-to-label line of high-quality, marketable hemp-derived CBD products for a variety of uses and industries.

Mr. John Westlake, founder and president of CCF, commented, “I am excited to partner with PBI by expanding my CBD processing and manufacturing license at PBI’s South Easton location. I strongly believe that I can leverage my many years to the cannabis market and hundreds of industry connections to help PBI get to market quickly and efficiently with its unique, highly stable, water-soluble hemp-derived CBD nanoemulsions processed through its class-leading UST platform worldwide”.

Using the company’s patented Ultra Shear Technology™ (“UST™”) platform, PBI will manufacture and sell, through a toll processing center located at its South Easton MA facility, a new generation of nanoemulsions of CBD derived from hemp soluble in water, in bulk format. Primarily expected to be purchased by formulators and manufacturers both in MA and across the U.S., PBI’s nano-CBD is expected to introduce revolutionary precise and effective dosing of nanoemulsified hemp-derived CBD into a wide variety of clean and stable labels. (which do not contain chemical preservatives), which include the nutraceuticals, personal care products, cosmetics and food and beverage markets, to name a few.

Mr. Kenneth F. Micciche, Director of Business Development at PBI, stated, “We are delighted that our facility has been inspected and approved by the Department of Agricultural Resources (“MDAR”). We can now begin a new phase for our business, to produce and deliver the best water-soluble hemp-derived CBD nanoemulsions available for use in thousands of products, in MA and the U.S. We believe our nano-CBD will deliver absorption, quality, potency and unprecedented potency. reliable dosing and delivery control. CCF’s MDAR license, required to process hemp-derived CBD in MA, allows PBI to begin meeting customer demand and sign the production contracts we previously announced, and the many new ones to come, for the highest quality CBD nanoemulsions in a global market it is estimated to reach $16.6 billion by 2027.

Mr. Richard T. Schumacher, President and CEO of PBI, summarized: “We believe that our UST technology platform, along with CCF’s license to process/manufacture in MA and John’s impressive experience and remarkable contacts in the cannabis field , will greatly support the launch of our toll service model, driven by the delivery of high-value UST-processed CBD nanoemulsion products that deliver an enhanced experience resulting from better quality and bioavailability.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabled, pressure-based solutions for the life sciences and other global industries. Our products are based on the unique properties of constant (i.e. static) and alternating (i.e. Pressure Cycle Technology or PCT) hydrostatic pressure. PCT is a proprietary technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly monitor biomolecular interactions (eg, cell lysis, extraction of biomolecules). Our primary focus is on PCT-based product development for biomarker and target discovery, drug design and development, biotherapeutic characterization and quality control, soil and plant biology, forensics, and bioterrorism applications. In addition, significant new market opportunities have arisen in the use of our pressure-based technologies in the following areas: (1) the use of our patented technology recently acquired from BaroFold, Inc. (the “BaroFold” technology) to enable entry into the biopharmaceutical contract services industry, and (2) the use of our recently patented, scalable, high-efficiency Ultra Shear Technology (“UST”) platform and pressure-based to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized, low-acid, room-temperature-stable liquid foods of extended lifetimes that cannot be effectively preserved using existing non-thermal technologies.

Forward-looking statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that could cause actual results, levels of activity, performance or achievements in our industry or our industry to differ materially. different from future results or levels. of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “should,” “could,” “would,” “expect,” “plan,” “intend,” “anticipate.” ” “believes”, “estimates”, “predicts”, “projects”, “potential” or “continues” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider several factors. Actual events or results may differ materially. These and other factors could cause our actual results to differ materially from any forward-looking statements. risks, uncertainties and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and other reports submitted. for the time Company at I am with the SEC. The company assumes no obligation to update any of the information included in this release, unless otherwise provided by law.

For more information about PBI and this press release, please click on the following website link:

Visit us on Facebook, LinkedIn and Twitter.

Press contacts:
Richard T. Schumacher, President and CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Kenneth F. Micciche Director of Business Development (508) 230-1828(T)
John Westlake, President and Founder of Canopy CBD Farms, LLC. (978) 471-9981 (T)

SOURCE: Pressure BioSciences Inc.

View the source version at accesswire.com:

Source link

You May Also Like

About the Author: SteveSossin

Welcome! I keep up on all the latest cbd and thc news!